Barrington Research Reaffirms “Outperform” Rating for OPKO Health (NASDAQ:OPK)

OPKO Health (NASDAQ:OPK)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Barrington Research in a research note issued on Friday,Benzinga reports. They presently have a $2.25 price objective on the biotechnology company’s stock. Barrington Research’s target price suggests a potential upside of 32.74% from the company’s previous close.

OPK has been the topic of a number of other reports. HC Wainwright restated a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a report on Wednesday, January 8th. StockNews.com downgraded OPKO Health from a “hold” rating to a “sell” rating in a report on Wednesday, January 15th.

OPKO Health Trading Up 4.0 %

NASDAQ:OPK traded up $0.07 during mid-day trading on Friday, reaching $1.70. The company’s stock had a trading volume of 3,555,815 shares, compared to its average volume of 2,828,345. The company’s fifty day simple moving average is $1.55 and its two-hundred day simple moving average is $1.55. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health has a twelve month low of $0.86 and a twelve month high of $1.84. The stock has a market cap of $1.16 billion, a P/E ratio of -8.92 and a beta of 1.63.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The firm had revenue of $183.60 million for the quarter, compared to analyst estimates of $155.42 million. On average, equities analysts predict that OPKO Health will post -0.25 EPS for the current year.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 47,537 shares of the stock in a transaction on Tuesday, January 28th. The stock was purchased at an average price of $1.47 per share, for a total transaction of $69,879.39. Following the purchase, the chief executive officer now directly owns 213,234,014 shares in the company, valued at $313,454,000.58. This trade represents a 0.02 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders acquired a total of 1,322,537 shares of company stock worth $2,009,129 in the last 90 days. 47.26% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of OPKO Health by 24.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 753,380 shares of the biotechnology company’s stock worth $1,107,000 after acquiring an additional 148,322 shares in the last quarter. Two Sigma Advisers LP grew its position in shares of OPKO Health by 2.3% in the 4th quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock worth $560,000 after acquiring an additional 8,396 shares in the last quarter. Two Sigma Investments LP grew its position in shares of OPKO Health by 136.1% in the 4th quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company’s stock worth $2,422,000 after acquiring an additional 949,671 shares in the last quarter. ProShare Advisors LLC grew its position in shares of OPKO Health by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 91,730 shares of the biotechnology company’s stock worth $135,000 after acquiring an additional 30,182 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its position in shares of OPKO Health by 42.3% in the 4th quarter. Nuveen Asset Management LLC now owns 1,432,404 shares of the biotechnology company’s stock worth $2,106,000 after acquiring an additional 425,484 shares in the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.